SCHEMBL17070607

SCHEMBL17070607

COC(=O)Cc1ccc([18F])cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.63
CYP4A11 Q02928 1/20 0.63
KMT2A Q03164 4/20 0.63
MEN1 O00255 2/20 0.63
SMN1; SMN2 Q16637 3/20 0.55
KLK7 P49862 2/20 0.54
GAA P10253 4/20 0.53
MAPK1 P28482 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.52
HSP90AB1 P08238 1/20 0.52
ALDH1A1 P00352 1/20 0.51
GFER P55789 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
CA12 O43570 1/20 0.51
CA2 P00918 1/20 0.51
CA7 P43166 1/20 0.51
CA9 Q16790 1/20 0.51
CA14 Q9ULX7 1/20 0.51
LMNA P02545 1/20 0.50
HTT P42858 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL378218 1.00 CYP4F2 (0.63) CYP4F2CYP4A11KMT2AMEN1SMN1; SMN2
Nitrogen SCHEMBL27904011 0.96 KMT2A (0.60) CYP4F2CYP4A11KMT2AMEN1SMN1; SMN2
SCHEMBL17847702 0.94 KMT2A (0.58) CYP4F2CYP4A11KMT2AMEN1SMN1; SMN2
SCHEMBL31324158 0.91 MEN1 (0.63) CYP4F2CYP4A11KMT2AMEN1SMN1; SMN2
SCHEMBL7558146 0.91 KMT2A (0.56) CYP4F2CYP4A11KMT2AMEN1SMN1; SMN2
SCHEMBL4113212 0.89 CYP4F2 (0.76) CYP4F2CYP4A11KMT2ASMN1; SMN2GAA
SCHEMBL5090748 0.87 MAOB (0.63) KMT2AMEN1KLK7ALDH1A1CA12
Piperidine SCHEMBL28981230 0.87 KMT2A (0.52) CYP4F2CYP4A11KMT2AMEN1SMN1; SMN2
SCHEMBL754043 0.86 KMT2A (0.51) CYP4F2CYP4A11KMT2AMEN1SMN1; SMN2
SCHEMBL31324184 0.84 MEN1 (0.56) CYP4F2CYP4A11KMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9957231-B2 Iodine(II)-mediated radiofluorination THE GENERAL HOSPITAL CORPORATION (US) 2018-05-01 US disclosed
US-20160362375-A1 Iodine(III)-Mediated Radiofluorination THE GENERAL HOSPITAL CORPORATION 2016-12-15 US disclosed
US-9434699-B2 Iodine(III)-mediated radiofluorination THE GENERAL HOSPITAL CORPORATION (US) 2016-09-06 US disclosed
US-20150252007-A1 IODINE(III)-MEDIATED RADIOFLUORINATION THE GENERAL HOSPITAL CORPORATION 2015-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252007-A1 IODINE(III)-MEDIATED RADIOFLUORINATION TPO, FLI1, SSTR3 CYP4F2 167/4885CYP4A11 2886/4885KMT2A 1626/4885
US-20160362375-A1 Iodine(III)-Mediated Radiofluorination TPO, FLI1, SSTR3 CYP4F2 167/4885CYP4A11 2886/4885KMT2A 1626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.